This inventor holds 4 USPTO granted patents and 4 published patent applications. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Xiaojing Zheng: Innovator in Protein Measurement Technologies
Introduction
Xiaojing Zheng is a prominent inventor based in Croton-on-the-Hudson, NY (US). She has made significant contributions to the field of protein measurement, particularly in the area of post-translational modifications. Her innovative approach has the potential to enhance the accuracy of protein quantification, which is crucial in various biotechnological applications.
Latest Patents
Xiaojing Zheng holds a patent titled "Heavy peptide approach to accurately measure unprocessed C-terminal lysine." This patent provides a method for accurately measuring post-translational modifications in proteins, such as antibodies. The method utilizes heavy isotopic standards to generate a calibration curve, allowing for precise quantitation of modified peptides. This technique is particularly useful for quantifying C-terminal truncation in antibodies using mass spectrometry.
Career Highlights
Xiaojing Zheng is currently employed at Regeneron Pharmaceuticals, Inc., where she continues to advance her research in protein measurement technologies. Her work is instrumental in developing methods that improve the reliability of protein analysis, which is vital for therapeutic development and quality control in biopharmaceuticals.
Collaborations
Some of her notable coworkers include Tyler Greer and Milos Cejkov. Their collaborative efforts contribute to the innovative environment at Regeneron Pharmaceuticals, fostering advancements in biotechnological research.
Conclusion
Xiaojing Zheng's contributions to the field of protein measurement exemplify the impact of innovative thinking in biotechnology. Her patented methods enhance the accuracy of protein analysis, paving the way for advancements in therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
